Founded in 2005, Skingenix is a privately held, Southern California based company, specializing in the research and development of regenerative wound healing products. As an innovative and mission-driven company, Skingenix pursues a standard of excellence in the regenerative medical industry with an emphasis on developing organ in situ regenerative products for improving wound healing. Skingenix is currently pursuing a number of indications under an Investigational New Drug Application (IND) for their Investigational Drug Product MW-III in the USA.
As of 2013, the company has completed under FDA IND, three randomized and controlled multicenter clinical studies to assess the safety and efficacy of the new investigational drug in patients with Diabetic Foot Ulcers (DFU) and Venous Stasis Ulcers (VSUs). Other indications such as burn injuries and pressure ulcers are being pursued.
The investigational new drug MW-III is a proprietary botanical formulation derived from natural ingredients, that have been extensively described in the ancient Chinese Materia Medica and the current Chinese Pharmacopoeia. Based on the preliminary nonclinical pharmacological studies, the MW-III may maintain wounds in a physiological moist environment, reduce water evaporation from wounds, promote wound healing, improve wound microcirculation in the zone of stasis on burns, prevent wound infections, enhance re-epithelialization and skin repair, regeneration and improve overall quality of healing.